Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
November 17, 2024
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results
November 7, 2024
RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates
October 3, 2024
RegMedInvestors (RMi) Research Note: Editas Medicine asset sale raises $57+ M non -dilutive financing
September 10, 2024
RegMed Investors (RMi) Research Note: Ionis Pharmaceuticals (IONS) prices a $500.3 M public offering
August 30, 2024
RegMed Investors (RMi) Research Note: Harvard Apparatus RT (OTCQB: HRGN) raises $5 M without name identification
August 19, 2024
RegMed Investors (RMI) Research Note: Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Reports Q2/24 results
July 15, 2024
RegMed Investors (RMi) Research note: LENZ Therapeutics (LENZ +$0.16 to $21.19 at open) $30 M PIPE financing
March 22, 2024
RegMed Investors (RMi) research note – Finance: Sangamo Therapeutics (SGMO) Proposes Offering of 24,761,905 shares priced at $0.84
March 18, 2024
RegMedInvestors (RMi) Research Note – finance: bluebird bio (BLUE)Secures up to $175 M Debt Financing with Hercules Capital
March 6, 2024
RegMed Investors (RMi) Research Note – Financing: Regenxbio (RGNX) prices 4.56 M share offering at $23.00
February 21, 2024
RegMed Investors (RMi) Research Note:CRISPR Therapeutics (CRSP) announces Registered Direct Offering (RDO) of $280 M priced at $71.50 per share
February 20, 2024
RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes
February 15, 2024
RegMed Investors (RMi) Research Note: Prime Medicine (PRME) Prices 19million share offering at $6.25
February 13, 2024
RegMed (RMI) Research Note: CRISPR Therapeutics (CRSP) Registered Direct Offering (RDO) $280 M offering priced at $71.50
February 5, 2024
RegMed Investors (RMi): Adverum Biotechnologies (ADVM) 106.25 M Share Private Placement priced at $1.20
January 18, 2024
RegMed Investors (RMi) Research Note: Mesoblast (MESO) FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L)
January 8, 2024
RegMed Investors (RMi) Research Note: Solid Biosciences (SLDB) Announces $109 Million Private Placement
January 5, 2024
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) prices 7.77 M share public offering at $9.00 per share
January 2, 2024
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) juices after Novartis (NVS) licensing deal
December 22, 2023
Merry Christmas and Happy Holiday to All
December 20, 2023
RegMed Investors (RMi): bluebird bio (BLUE) prices $1.50 for 83 m stock offering
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.